Exyte acquires TTP Group to accelerate growth of biopharma and life sciences business
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
TTP Group is a leading engineering firm specializing in biotech and pharmaceutical industry
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
To accelerate the development of next-generation radioconjugates to treat cancer
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
Subscribe To Our Newsletter & Stay Updated